European urology
-
Comparative Study
A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006.
The efficacy of prostate cancer (PCa) treatment modalities is a subject of continuous debate. ⋯ Our results showed that RP provides the most favorable survival rates in most patients. The exception is octogenarian men, in whom RT provides the best results. Finally, the least-favorable outcomes were recorded after observation. However, these findings must be interpreted within the context of the limitations of observational data.
-
Practice Guideline
EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.
Our aim was to present a summary of the 2010 version of the European Association of Urology (EAU) guidelines on the screening, diagnosis, and treatment of clinically localised cancer of the prostate (PCa). ⋯ The knowledge in the field of PCa is rapidly changing. These EAU guidelines on PCa summarise the most recent findings and put them into clinical practice.
-
Review Meta Analysis
Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis.
Treatment of neurogenic lower urinary tract dysfunction (LUTD) is a challenge, because conventional therapies often fail. Sacral neuromodulation (SNM) has become a well-established therapy for refractory non-neurogenic LUTD, but its value in patients with a neurologic cause is unclear. ⋯ There is evidence indicating that SNM may be effective and safe for the treatment of patients with neurogenic LUTD. However, the number of investigated patients is low with high between-study heterogeneity, and there is a lack of randomised, controlled trials. Thus, well-designed, adequately powered studies are urgently needed before more widespread use of SNM for neurogenic LUTD can be recommended.